Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + ezetimibe + rosuvastatin + telmisartan
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-231A + AD-231D + AD-231C is a combination regimen consisting of four active pharmaceutical ingredients: **telmisartan**, **amlodipine**, **rosuvastatin**, and **ezetimibe**, administered as separate components. Developed by Addpharma Inc., this regimen is used as the reference comparator arm in Phase 1 clinical trials to evaluate the bioequivalence, safety, and pharmacokinetics of the fixed-dose combination (FDC) tablet AD-231. The combination targets multiple cardiovascular risk factors by addressing both hypertension and dyslipidemia. Telmisartan acts as an angiotensin II receptor blocker (ARB), amlodipine as a dihydropyridine calcium channel blocker (CCB), rosuvastatin as an HMG-CoA reductase inhibitor (statin), and ezetimibe as a selective cholesterol absorption inhibitor.
- Other names
- AD-231A, AD-231D and AD-231C co-administration
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on amlodipine + ezetimibe + rosuvastatin + telmisartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + ezetimibe + rosuvastatin + telmisartan.